Abexinostat (CRA-024781, CRA024781, CAS: 783355-60-2) is a small molecule histone deacetylase (HDAC) inhibitor that has been investigated as a potential therapeutic agent for cancer. It has demonstrated efficacy in preclinical and clinical studies for the treatment of various types of cancer, including lymphoma, leukemia, and solid tumors.
Chemical name: N-hydroxy-4-{[(2-methyl-1H-indol-3-yl)methyl]amino}benzamide
Molecular formula: C16H15N3O2
Formula weight: 277.31 g/mol
CAS No: 783355-60-2
Top ten keywords from Google:
Synonyms:
Health benefits of this product: Abexinostat has demonstrated potential health benefits in the area of cancer research, particularly in the treatment of lymphoma, leukemia, and solid tumors. Its primary mode of action is through inhibition of HDAC enzymes, leading to increased acetylation of histones and subsequent alterations in gene expression.
Potential effects: Abexinostat has demonstrated efficacy in several preclinical and clinical studies in inhibiting HDAC activity and altering gene expression. It also has potential benefits for inducing apoptosis (programmed cell death), reducing angiogenesis (the formation of new blood vessels that can support tumor growth), and enhancing the immune response to cancer cells. Abexinostat works by disrupting various cellular processes that are necessary for cancer cell survival and growth.
Product mechanism: Abexinostat works by inhibiting HDAC enzymes, which are involved in the regulation of gene expression. By inhibiting these enzymes, abexinostat can increase histone acetylation and subsequent alterations in gene expression, leading to reduced tumor growth and increased apoptosis.
Safety: Abexinostat has been evaluated in several preclinical and clinical trials involving hundreds of participants and has been generally well-tolerated. Common side effects may include gastrointestinal symptoms such as nausea, vomiting, and diarrhea, as well as hematological abnormalities (e.g., decreased white blood cell or platelet counts) and hepatic dysfunction. Patients with liver or kidney disease should exercise caution when taking abexinostat, as it may affect these conditions. Pregnant or breastfeeding women should avoid using abexinostat, as its safety in these populations has not been established.
Side effects: Less common but more severe side effects of abexinostat may include bleeding disorders, cardiovascular events, and liver or kidney dysfunction, which may require prompt medical intervention. Patients should be monitored closely for these adverse events and receive appropriate medical intervention if necessary.
Dosing information: The optimal dose and dosing regimen of abexinostat may vary depending on the patient's condition and treatment goals. In preclinical studies, doses ranging from 10 to 200 mg have been evaluated for various types of cancer. Patients should follow their doctor's instructions regarding dosing, administration, and monitoring.
Conclusion: Abexinostat (CRA-024781, CRA024781, CAS: 783355-60-2) is a small molecule HDAC inhibitor that has been investigated as a potential therapeutic agent for cancer, particularly in the treatment of lymphoma, leukemia, and solid tumors. Although it has been generally well-tolerated in preclinical and clinical trials, it may cause some side effects that should be monitored closely. More research is needed to determine its full potential and efficacy in different patient populations and cancer types. Abexinostat offers a promising avenue for epigenetic treatment of cancer by altering gene expression and inhibiting tumor growth
